This clinical trial is focused on studying the effects of a treatment for patients with end-stage renal disease who are undergoing kidney transplantation. The study will compare the use of a solution called mannitol with normal saline in individuals who have received a kidney from a brain-dead donor. The main goal is to determine if mannitol can help improve the success of kidney transplants by reducing a condition known as delayed graft function, which is when the new kidney takes longer than expected to start working properly.
Participants in the study will receive either mannitol or a placebo, which is a substance with no active treatment, through an intravenous infusion. The study will monitor how quickly the transplanted kidney begins to function and will also look at other factors such as the occurrence of acute kidney graft rejection within three months and the kidney’s performance at different time points, including seven days, one month, and three months after the transplant.
The trial aims to provide valuable information on whether mannitol can be a beneficial treatment option for improving outcomes in kidney transplant patients. The study will be conducted over a period of time, with participants being closely monitored to assess the effectiveness and safety of the treatment. This research could potentially lead to better management strategies for patients undergoing kidney transplantation, ultimately improving their quality of life.
Finland 
